Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial - Motzer, RJ; Escudier, B; McDermott, DF (J Immunother Cancer, 2020)
et al.